![Virtual Booth](https://www.pharmacompass.com/image/vb/vb-orange-btn.png)
![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euroapi-corp-ad-w30-desktop-header-1-2gif-57087.gif)
![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euro-api-mob-header-w30gif-19381.gif)
Active Filter(s):
Details:
The net proceeds are expected to be used for geographic expansion of the contract research activities, continued development of the drug candidate pipeline including amylin for the treatment of obesity, technological solutions and proprietary platforms as well as acquisitions.
Lead Product(s): Amylin
Therapeutic Area: Nutrition and Weight Loss Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Peptide
Partner/Sponsor/Collaborator: Skandinaviska Enskilda Banken
Deal Size: $71.6 million Upfront Cash: Undisclosed
Deal Type: Public Offering March 06, 2023